Omaha, NE-based Meridian Clinical Research is strategically aligned with seven top-10 sponsors and eight of the top-10 contract research organizations (CROs), according to the company, which supports more than 60 principal investigators.
Members of the broader clinical trial site network, Platinum Research Network, Meridian and Regional Clinical Research have collaborated in the past.
Regional was established in 1993 and operates four research sites in New York and has 10 principal investigators.
Meridian CEO, Nicole Osborn, said the acquisition is a response to growing client demands for expanded relationships.
“The acquisition reinforces therapeutic depth in key areas — including vaccines/infectious diseases, neurology, and women’s health — while giving Meridian a way to expand operations in a sustainable way,” she told us.
“Clients and partners can expect business as usual, with enhanced service offerings coming soon,” Osborn added. “Together, Meridian and Regional will combine resources and therapeutic depth to provide richer clinical research capabilities and greater access to patients.”